Hyperparathyroidism medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 61: | Line 61: | ||
*3. Secondary hyperparathyroidism | *3. Secondary hyperparathyroidism | ||
**3.1 Calcimimetic drugs<ref name="pmid28518414">{{cite journal| author=Dulfer RR, Franssen GJH, Hesselink DA, Hoorn EJ, van Eijck CHJ, van Ginhoven TM| title=Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. | journal=Br J Surg | year= 2017 | volume= 104 | issue= 7 | pages= 804-813 | pmid=28518414 | doi=10.1002/bjs.10554 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28518414 }} </ref> | **3.1 Calcimimetic drugs<ref name="pmid28518414">{{cite journal| author=Dulfer RR, Franssen GJH, Hesselink DA, Hoorn EJ, van Eijck CHJ, van Ginhoven TM| title=Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. | journal=Br J Surg | year= 2017 | volume= 104 | issue= 7 | pages= 804-813 | pmid=28518414 | doi=10.1002/bjs.10554 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28518414 }} </ref> | ||
**:*Preferred regimen (1): Cinacalcet HCL | |||
==References== | ==References== | ||
Revision as of 19:16, 29 August 2017
|
Hyperparathyroidism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hyperparathyroidism medical therapy On the Web |
|
American Roentgen Ray Society Images of Hyperparathyroidism medical therapy |
|
Risk calculators and risk factors for Hyperparathyroidism medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
Medical therapy for hyperparathyroidism should be considered in the following circumstances:[1]
- Patients with primary hyperparathyroidism not meeting the guidelines for surgery.
- Patients with primary hyperparathyroidism having contraindications to surgery.
- Patient with primary hyperparathyroidism who have previous unsuccessful neck exploration.
- Patient with primary hyperparathyroidism who have not been cured by surgery.
- Patient with primary hyperparathyroidism refuses surgery.
Monitoring
Patients with primary hyperparathyroidism who do not undergo parathyroidectomy should be monitored for the potential progression of disease. There are guidelines for monitoring of patients with asymptomatic hyperparathyroidism not undergoing parathyroidectomy. These guidelines include:[2]
- Serum calcium
- Serum calcium should be monitored annually.
- Skeletal monitoring
- Dual-energy X-ray absorptiometry (DEXA) is used for skeletal monitoring. DEXA should be done every 1-2 years (at 3 sites).
- X-ray or vertebral fracture assessment of spine may be done if indications are present such as height loss, and/or back pain.
- Renal monitoring
- Estimated glomerular filtration rate (eGFR) and serum creatinine should be done annually.
- 24-h biochemical stone profile, renal imaging by x-ray, ultrasound, or CT scan may be considered if renal stones are suspected.
Medical Management
- 1. Primary hyperparathyroidism
- 1.1 Nutritional supplementation[3]
- 1.1.1 Low calcium intake[4]
- Preferred regimen (1): Elemental calcium 500 mg PO q24h
- Note: Dietary calcium restriction is not necessary in primary hyperparathyroidism.
- 1.1.2 Vitamin D depletion
- Preferred regimen (1): Cholecalciferol 600–1000 IU PO q24h
- Note(1): Vitamin D deficiency is considered when serum level of 25-hydroxy vitamin D is below 50 nM (20 ng/mL).[5]
- Note(2): Serum calcium levels and urinary calcium excretion should be monitored during vitamin D supplementation. Vitamin D supplementation should be stopped if serum calcium levels is >11.6 mg/dL and/or urinary calcium excretion is >400 mg/24 h.
- Note(3): The goal of vitamin D supplementation is to keep 25-hydroxy vitamin D level between 50 nmol/L to 75 nmol/L.
- 1.1.1 Low calcium intake[4]
- 1.2 Pharmacotherapy
- 1.2.1 Estrogen Receptor-Targeted Therapy (Post-menopausal women)
- Preferred regimen (1): Conjugated equine estrogen 0.625 mg q24h + medroxyprogesterone acetate 5mg q24h
- Note(1): The risk-benefit ratio should be assessed with respect to known relative or absolute contraindication to use of estrogen in each patient.
- 1.2.2 Bisphosphonates
- 1.2.3 Calcimimetics
- Note(1): Cincalcet may be used in patients with familial primary hyperparathyroidism as a treatment option for patients having recurrent or persistent hypercalcemia after parathyroidectomy.
- Note(2): A combination of bisphosphonates and calcimimetics may be used to reduce the serum calcium and improve BMD.[10]
- 1.2.1 Estrogen Receptor-Targeted Therapy (Post-menopausal women)
- 1.1 Nutritional supplementation[3]
- 2. Secondary hyperparathyroidism[11]
- 2.1 Secondary hyperparathyroidism due to vitamin D deficiency
- 2.1.1 Vitamin D analogs
- Preferred regimen (1): Calcitriol
- Preferred regimen (2): Paricalcitol
- Preferred regimen (3): Doxercalciferol
- 2.1.1 Vitamin D analogs
- 2.2 Secondary hyperparathyroidism due to Chronic renal failure
- 2.2.1 Calcimimetics[12][13]
- Preferred regimen (1): Cinacalcet HCL 30-180 mg PO q24h
- 2.2.2 Phosphate binders/phosphate restriction
- 2.2.3 Vitamin D analogs[14][15]
- Preferred regimen (1): Calcitriol 0.5 μg thrice weekly
- Preferred regimen (2): Paricalcitol 2 μg thrice weekly
- Preferred regimen (3): Doxercalciferol 1 μg thrice weekly
- 2.2.1 Calcimimetics[12][13]
- 2.1 Secondary hyperparathyroidism due to vitamin D deficiency
- 3. Secondary hyperparathyroidism
- 3.1 Calcimimetic drugs[16]
- Preferred regimen (1): Cinacalcet HCL
- 3.1 Calcimimetic drugs[16]
References
- ↑ Khan AA (2013). "Medical management of primary hyperparathyroidism". J Clin Densitom. 16 (1): 60–3. doi:10.1016/j.jocd.2012.11.010. PMID 23374743.
- ↑ Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C; et al. (2014). "Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop". J Clin Endocrinol Metab. 99 (10): 3561–9. doi:10.1210/jc.2014-1413. PMC 5393490. PMID 25162665.
- ↑ Marcocci C, Bollerslev J, Khan AA, Shoback DM (2014). "Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism". J Clin Endocrinol Metab. 99 (10): 3607–18. doi:10.1210/jc.2014-1417. PMID 25162668.
- ↑ Jorde R, Szumlas K, Haug E, Sundsfjord J (2002). "The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake". Eur J Nutr. 41 (6): 258–63. doi:10.1007/s00394-002-0383-1. PMID 12474069.
- ↑ Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK; et al. (2011). "The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know". J Clin Endocrinol Metab. 96 (1): 53–8. doi:10.1210/jc.2010-2704. PMC 3046611. PMID 21118827.
- ↑ Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT; et al. (2003). "Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism". J Clin Endocrinol Metab. 88 (2): 581–7. doi:10.1210/jc.2002-020890. PMID 12574184.
- ↑ Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY; et al. (2004). "Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial". J Clin Endocrinol Metab. 89 (7): 3319–25. doi:10.1210/jc.2003-030908. PMID 15240609.
- ↑ Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D (2005). "Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism". J Clin Endocrinol Metab. 90 (1): 135–41. doi:10.1210/jc.2004-0842. PMID 15522938.
- ↑ Luque-Fernández I, García-Martín A, Luque-Pazos A (2013). "Experience with cinacalcet in primary hyperparathyroidism: results after 1 year of treatment". Ther Adv Endocrinol Metab. 4 (3): 77–81. doi:10.1177/2042018813482344. PMC 3666442. PMID 23730501.
- ↑ Faggiano A, Di Somma C, Ramundo V, Severino R, Vuolo L, Coppola A; et al. (2011). "Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism". Endocrine. 39 (3): 283–7. doi:10.1007/s12020-011-9459-0. PMID 21445714.
- ↑ Wetmore JB, Quarles LD (2009). "Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?". Nat Clin Pract Nephrol. 5 (1): 24–33. doi:10.1038/ncpneph0977. PMC 3924719. PMID 18957950.
- ↑ Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC (2006). "Meta-analysis of biochemical and patient-level effects of calcimimetic therapy". Am J Kidney Dis. 47 (5): 715–26. doi:10.1053/j.ajkd.2006.01.015. PMID 16632010.
- ↑ Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA; et al. (2005). "Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl". Kidney Int. 67 (2): 760–71. doi:10.1111/j.1523-1755.2005.67139.x. PMID 15673327.
- ↑ Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA; et al. (2008). "Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism". Nephrol Dial Transplant. 23 (7): 2311–8. doi:10.1093/ndt/gfn026. PMID 18310602.
- ↑ Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM; et al. (2006). "Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate". Clin J Am Soc Nephrol. 1 (2): 305–12. doi:10.2215/CJN.00870805. PMID 17699221.
- ↑ Dulfer RR, Franssen GJH, Hesselink DA, Hoorn EJ, van Eijck CHJ, van Ginhoven TM (2017). "Systematic review of surgical and medical treatment for tertiary hyperparathyroidism". Br J Surg. 104 (7): 804–813. doi:10.1002/bjs.10554. PMID 28518414.